HUR1 Antibody

What is HUR1 and what cellular functions does it perform?

HUR1 (Human antigen R 1) exhibits different functions across various organisms. In yeast (Saccharomyces cerevisiae), HUR1 is identified under Uniprot No. P45820 and serves as a cellular protein with specific functions in DNA damage response mechanisms . In human contexts, HUR1 has been observed as an RNA-binding protein involved in post-transcriptional regulation. Notably, in the context of pathogen-host interactions, HUR1 binds to AU-rich elements in the 3'UTR of certain mRNAs, such as CXCL10, affecting their translation . This binding activity suggests HUR1 functions in regulating gene expression at the post-transcriptional level, particularly during cellular stress responses.

What are the optimal storage conditions for HUR1 antibodies?

For maximum stability and retention of binding efficacy, HUR1 antibodies should be stored at -20°C to -80°C immediately upon receipt. Repeated freeze-thaw cycles should be strictly avoided as these can significantly degrade antibody quality and compromise experimental results . Most HUR1 antibodies are formulated in a storage buffer containing 50% glycerol, 0.01M PBS at pH 7.4, with 0.03% Proclin 300 as a preservative . This formulation helps maintain antibody stability during storage. When retrieving antibodies for experiments, aliquoting into single-use volumes is strongly recommended to prevent quality deterioration from repeated temperature fluctuations.

What experimental applications are validated for HUR1 antibodies?

HUR1 antibodies have been validated primarily for Enzyme-Linked Immunosorbent Assay (ELISA) and Western Blot (WB) applications, particularly for identification of target antigens . Additionally, HUR1 antibodies have been successfully employed in native RNA Immunoprecipitation (RIP) assays to investigate RNA-protein interactions, as demonstrated in studies examining the binding between HUR1 and CXCL10 mRNA . When implementing these techniques, researchers should include appropriate positive and negative controls; for example, in RIP assays, anti-HSP70 antibody has been utilized as a negative control to validate the specificity of HUR1-RNA interactions .

How does HUR1 participate in RNA-binding mechanisms?

HUR1 functions as an RNA-binding protein that specifically recognizes and binds to AU-rich elements (AREs) within the 3'UTR regions of target mRNAs . This binding activity plays a critical role in regulating mRNA stability and translation efficiency. Research has demonstrated that HUR1 binding to the CXCL10 transcript involves a specific small RNA domain (92 bp) enriched with AU-elements located at the 3'UTR . The binding mechanism appears to be triggered through a cascade involving pathogen-derived extracellular vesicles and subsequent activation of the retinoic acid-inducible gene-I protein (RIG-I) . When investigating HUR1-RNA interactions, researchers should consider using native RIP assays with stringent controls to preserve the integrity of physiological RNA-protein complexes.

What role does HUR1 play in inflammatory regulation?

Evidence suggests HUR1 serves as a significant post-transcriptional regulator in inflammatory pathways. In the context of pathogen-host interactions, specifically during Plasmodium falciparum infection, HUR1 contributes to inflammatory regulation by binding to AU-rich elements in the 3'UTR of CXCL10 mRNA, which subsequently inhibits CXCL10 protein translation . This mechanism represents a remarkable example of how pathogens can manipulate host inflammatory responses through RNA-binding proteins. Additionally, related RNA-binding protein HuR (ELAVL1) has been shown to suppress inflammation in intervertebral disc degeneration contexts, with decreased expression correlating with increased inflammatory mediators such as IL-6, IL-1β, TNF-α, and iNOS . These findings highlight the complexity of HUR1 and related proteins in modulating inflammatory processes across different biological systems.

How is HUR1 implicated in host-pathogen interactions?

HUR1 plays a crucial role in a sophisticated molecular mechanism exploited by Plasmodium falciparum to regulate host immune responses. Research has revealed that P. falciparum produces extracellular vesicles containing RNA cargo that, upon internalization by host monocytes, triggers the RIG-I pathway . This activation leads to recruitment of HUR1, which binds specifically to AU-rich domains within the CXCL10 mRNA 3'UTR, effectively blocking translation of this important chemokine . This represents a remarkable example of pathogen manipulation of host post-transcriptional regulation mechanisms. The inhibition of CXCL10 synthesis appears to be beneficial for parasite survival during early infection stages, though interestingly, when CXCL10 levels eventually rise, the parasite shifts to a growth acceleration strategy . This complex interaction demonstrates how HUR1 functions as a critical component in host-pathogen molecular dialogue.

What are the critical considerations for validating HUR1 antibody specificity?

Validating HUR1 antibody specificity requires a multi-faceted approach. First, researchers should conduct side-by-side comparisons with known positive controls and evaluate species cross-reactivity carefully, particularly since HUR1 antibodies may exhibit different specificities across species (e.g., yeast vs. human systems) . Second, implement competitive binding assays using recombinant HUR1 protein as a blocking agent to confirm binding specificity. Third, include knockout or knockdown controls whenever possible, using techniques such as CRISPR-Cas9 or RNAi to eliminate or reduce HUR1 expression. Fourth, perform immunoblotting to verify that the antibody detects a protein of the expected molecular weight, considering that HUR1 from Saccharomyces cerevisiae has distinct characteristics from mammalian variants . Finally, cross-validate findings using multiple antibodies targeting different epitopes of HUR1 to ensure consistency of results.

How can researchers optimize RNA immunoprecipitation (RIP) assays using HUR1 antibodies?

Successful RNA immunoprecipitation using HUR1 antibodies requires careful optimization. Begin with crosslinking optimization, testing different formaldehyde concentrations (0.1-1%) and incubation times to preserve RNA-protein interactions without overfixing. Use fresh cellular lysates and maintain cold conditions throughout the protocol to prevent RNA degradation. The antibody concentration should be empirically determined; typically starting with 5 μg per immunoprecipitation reaction and adjusting based on results . Include appropriate negative controls such as anti-HSP70 antibody and non-specific IgG to distinguish between specific and non-specific binding . For HUR1-specific considerations, optimize lysis conditions to preserve the integrity of AU-rich element interactions, potentially using low-salt buffers supplemented with RNase inhibitors. Consider fragmenting RNA prior to immunoprecipitation to improve resolution of binding sites. For detection of specific transcripts like CXCL10, design primers targeting the AU-rich regions in the 3'UTR where HUR1 binding occurs . Finally, validate findings through complementary approaches such as EMSA (Electrophoretic Mobility Shift Assay) or RNA pull-down assays.

What techniques can researchers use to investigate HUR1's role in post-transcriptional regulation mechanisms?

Investigating HUR1's role in post-transcriptional regulation requires a comprehensive toolkit. Researchers should implement CLIP-seq (Cross-Linking Immunoprecipitation followed by sequencing) to identify genome-wide RNA targets of HUR1 binding, with particular attention to AU-rich elements in 3'UTRs . RNA stability assays using actinomycin D chase experiments can determine whether HUR1 binding stabilizes or destabilizes target transcripts. Polysome profiling coupled with HUR1 depletion studies will reveal effects on translation efficiency of target mRNAs. For specific targets like CXCL10, reporter gene assays incorporating wild-type and mutated AU-rich elements from the 3'UTR can directly assess the functional impact of HUR1 binding . In pathogen interaction studies, researchers should employ extracellular vesicle isolation and RNA content analysis to investigate the mechanisms by which pathogens like P. falciparum deliver RNA cargo that influences HUR1 activity . Additionally, proximity ligation assays can visualize interactions between HUR1 and other components of the post-transcriptional machinery in situ, providing spatial context for these regulatory mechanisms.

How does HUR1 expression pattern correlate with disease progression?

Emerging evidence suggests HUR1 expression patterns may serve as indicators of disease progression in various contexts. In intervertebral disc degeneration (IVDD), the related RNA-binding protein HuR (ELAVL1) shows progressively decreased expression as disc degeneration advances through Pfirrmann grades II, III, and IV, as confirmed by qPCR analysis of nucleus pulposus tissues . This downregulation correlates with increased expression of inflammatory mediators, suggesting a protective role for HuR against inflammation in normal disc tissues . In infectious disease contexts, particularly malaria, HUR1 activity appears to be manipulated by Plasmodium falciparum as part of a sophisticated immune evasion strategy . When investigating HUR1 as a potential biomarker, researchers should employ multiplexed approaches, combining qPCR, Western blotting, and immunohistochemistry to comprehensively profile expression patterns across different tissue compartments and disease stages. Time-course studies are particularly valuable to track dynamic changes in HUR1 expression during disease progression, as demonstrated in the TNF-α dose and time-dependent studies of HuR in nucleus pulposus cells .

What are the common pitfalls when working with HUR1 antibodies in different experimental platforms?

Researchers working with HUR1 antibodies frequently encounter several technical challenges. First, cross-reactivity issues may arise, particularly when distinguishing between HUR1 and other RNA-binding proteins with similar structural domains . This problem can be addressed through careful antibody selection with validated specificity for the target species and performing comprehensive blocking studies. Second, variable immunoreactivity across different sample preparations may occur, especially in fixed tissues where epitope masking can reduce detection sensitivity. Optimize antigen retrieval methods by testing multiple protocols (e.g., varying trypsin concentration and incubation time as seen in the IVDD studies) . Third, high background signal in immunohistochemistry applications can interfere with accurate quantification. This issue can be mitigated by extending blocking periods with appropriate serum (e.g., 1% goat serum albumin for at least 1 hour at 37°C) . Fourth, inconsistent results in RIP assays may stem from RNA degradation during processing. Incorporate RNase inhibitors throughout all experimental steps and maintain strict cold-chain procedures. Finally, for polyclonal antibodies like the one described in result , lot-to-lot variability may affect experimental reproducibility; whenever possible, reserve sufficient antibody from a single lot for complete experimental series.

How can researchers differentiate between the functions of HUR1 and related RNA-binding proteins?

Distinguishing the specific functions of HUR1 from related RNA-binding proteins requires sophisticated experimental approaches. Implement CRISPR-Cas9 mediated knockout of HUR1 followed by rescue experiments with either wild-type HUR1 or related proteins to determine functional uniqueness versus redundancy. Conduct comparative RNA-seq following selective depletion of individual RNA-binding proteins to identify unique versus overlapping target transcripts. For investigating binding preferences, perform in vitro binding assays with purified proteins and synthetic RNA oligonucleotides containing various AU-rich element configurations. In the context of host-pathogen interactions, design time-course experiments that track the sequential recruitment of different RNA-binding proteins to specific target mRNAs like CXCL10 . Employ proximity labeling techniques such as BioID or APEX to identify unique protein interaction networks for HUR1 versus related proteins in living cells. For distinguishing between the function of HUR1 in yeast versus its human ortholog, comparative evolutionary analyses coupled with domain swapping experiments can reveal conserved versus species-specific functions . When examining inflammatory regulation, particularly in contexts like intervertebral disc degeneration, use dual knockdown approaches to assess potential compensatory mechanisms between HUR1 and related proteins like ELAVL1 .

What emerging technologies might enhance HUR1 antibody-based research?

Several cutting-edge technologies hold promise for advancing HUR1 antibody applications in research. Single-cell approaches combining immunolabeling with transcriptomics will enable researchers to correlate HUR1 protein levels with target mRNA expression at unprecedented resolution. Super-resolution microscopy techniques like STORM or PALM, when combined with HUR1 antibodies, can visualize the spatial organization of HUR1-containing ribonucleoprotein complexes at nanoscale resolution. Advances in CUT&Tag technology may allow precise mapping of HUR1 binding sites across the transcriptome with improved signal-to-noise ratios compared to traditional CLIP-seq approaches. For therapeutic applications, especially in contexts like malaria where HUR1 plays a role in host-pathogen interactions, the development of bispecific antibodies targeting both HUR1 and pathogen-derived factors could provide novel intervention strategies . Additionally, the emerging field of spatially resolved transcriptomics may be combined with HUR1 immunodetection to map the regional distribution of HUR1-regulated transcripts in tissues, particularly valuable for heterogeneous samples like degenerating intervertebral discs .

How might understanding HUR1 function contribute to novel therapeutic approaches?

The detailed characterization of HUR1's role in post-transcriptional regulation opens several promising therapeutic avenues. In inflammatory conditions like intervertebral disc degeneration, where related protein HuR expression inversely correlates with inflammation markers, targeted approaches to stabilize or enhance HUR1/HuR activity could potentially attenuate inflammatory cascades . Conversely, in infectious disease contexts like malaria, where Plasmodium falciparum manipulates HUR1 to suppress host CXCL10 production, therapeutic strategies might aim to block this interaction, potentially enhancing protective immune responses . Small molecule modulators that specifically target HUR1 binding to AU-rich elements could be developed as a novel class of drugs for conditions where aberrant mRNA stability contributes to pathology. Gene therapy approaches using CRISPR-Cas9 to modify the binding capacity of HUR1 to specific target transcripts represent another frontier. For immunotherapy applications, particularly in contexts where CXCL10 regulation is critical, combination approaches targeting both HUR1 and downstream chemokine pathways might yield synergistic effects. Future research should prioritize high-throughput screening of compounds that selectively modulate HUR1 binding to specific target transcripts, potentially enabling transcript-selective intervention with fewer off-target effects than direct protein inhibition.